# PT-141 Research: The Preclinical, Clinical & fMRI Record > PT-141 (bremelanotide) research, cited: rat and primate pharmacology, the RECONNECT Phase 3 trials, the fMRI mechanism study, and the critical re-analysis. A terse literature digest. From c-Fos in rat hypothalamus to two Phase 3 RCTs and a critical re-analysis. Every quantitative claim cites a study. ## Start here PT-141 research runs from receptor pharmacology to large human trials. The thread is consistent: this is a brain-acting peptide for desire. Early work in rats and nonhuman primates showed it switches on melanocortin receptors and fires hypothalamic neurons [1]. Female-rat work showed it raises desire-driven behavior specifically [2]. Then two large trials in women confirmed a real, modest benefit for low desire, with nausea as the main cost [3][4]. A brain-imaging study showed the effect on desire and on how the brain processes erotic cues directly [5]. The record is honest about limits. A re-analysis argues the trial effects are small [14]. A 2025 hamster study found the peptide did not enhance sexual *reward* in that model — a nuanced, partly-negative result [6]. Below, each finding is logged to its source, organized by what was studied. ## Preclinical pharmacology The first pharmacology established central action. PT-141, a synthetic alpha-MSH analogue, is an agonist at MC3R/MC4R expressed primarily in the CNS; systemic dosing produced penile erections in rats and nonhuman primates, activated hypothalamic neurons (increased c-Fos), and produced rapid dose-dependent erectile activity in men with erectile dysfunction in early studies [1]. Female-rat work isolated the desire signal. PT-141 selectively stimulated appetitive (solicitational) sexual behavior without affecting lordosis, pacing, or general motor activity — evidence that central melanocortin systems regulate female sexual desire, and the first pharmacological agent reported to act on appetitive female sexual behavior [2]. A 2025 hamster study added nuance: MC3R/MC4R mRNA concentrated in ventral-tegmental-area dopamine neurons, but bremelanotide did not change melanocortin-receptor expression in the mesolimbic system and did not enhance sexual reward (conditioned place preference) — suggesting it does not act on the VTA-NAc reward circuit [6]. ## PT-141 for women — the Phase 3 record The pivotal evidence is RECONNECT: two identical Phase 3 RCTs in 1,267 premenopausal women with HSDD. Bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and reduced desire-related distress (integrated FSDS-DAO item 13, -0.33, P<.001) versus placebo over 24 weeks [3]. Coprimary endpoints were met in both trials; the most common adverse events were nausea, flushing, and headache [3]. The 52-week open-label extension (684 women) showed sustained desire improvement and a stable safety profile, with nausea (40.4%) the principal tolerability issue [4]. This is the body of evidence behind the women-only approval. Mechanistic neuroimaging in 31 women with HSDD confirmed MC4R agonism raises desire and modulates central sexual brain processing [5]. ## PT-141 for men — the off-label evidence Evidence in men is earlier and off-label. The first pharmacology reported rapid, dose-dependent erectile activity in men with erectile dysfunction following systemic administration [1]. Early intranasal dose-escalation work reported a statistically significant erectile response above ~7 mg, but the intranasal route was later discontinued for pharmacokinetic variability [13]. Reviews of centrally acting agents and of novel erectile-dysfunction therapies position bremelanotide as a CNS-acting option distinct from vascular PDE-5 inhibitors, modulating hypothalamic and preoptic neurotransmission [10][13]. None of this male research led to approval — use in men remains off-label and investigational. Note: a 2008 erectile-dysfunction salvage study (Safarinejad & Hosseini) received a 2023 Expression of Concern and should be treated as disputed. ## Interpretation and open questions The findings converge on a central, desire-focused mechanism, validated in large human trials for one indication. The open questions are about magnitude and scope. A re-analysis of the Phase 3 data argues the effects on desire and distress are statistically significant but small, and questions the clinical meaningfulness of the chosen outcome measures [14]; a 2024 follow-up restates the critique [14]. The melanocortin system is also a leading target for metabolic disease, and bremelanotide's 2019 approval helped demonstrate the safety of this peptide class [8]. Reviews of the female sexual response frame melanocortins among the key excitatory neuromodulators of desire [11]. The unresolved scope: everything beyond premenopausal-HSDD desire — men, metabolic effects, performance — remains investigational or off-label. --- A two-ink lab-notebook digest of the PT-141 (bremelanotide) record — the central MC4R mechanism, the premenopausal-HSDD-only approval, and the nausea-led tolerability cost logged to source and overprinted in plain sight, with the research-chemical form kept clearly off-register from the approved drug; no clinic behind the press and nothing here dosed, dispensed, or sold.